Ganetespib

Generic Name: Ganetespib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀N_₄O_₃

CAS Number: 888216-25-9

Unique Ingredient Identifier: 2E8412Y946

Background: Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Phase 3

Terminated

Conditions: Non-Small-Cell Lung Adenocarcinoma
Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Docetaxel
Drug: Ganetespib

First Posted Date: 2013-02-25

Last Posted Date: 2016-07-01

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 696

Registration Number: NCT01798485

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 200 locations

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
HER-2 Positive Breast Cancer
ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Triple Negative Breast Cancer

Interventions: Drug: ganetespib

First Posted Date: 2012-09-03

Last Posted Date: 2015-11-05

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 51

Registration Number: NCT01677455

Locations: 🇬🇧
Synta Pharmaceuticals Investigative Site, Oxford, United Kingdom
🇬🇧
Synta Pharmaceutical Investigative Site, Peterborough, United Kingdom
🇰🇷
Synta Pharmacuetical Investigative Site, Seoul, Seodaemun-GU, Korea, Republic of

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Lung Cancer - Malignant Pleural Mesothelioma

Interventions: Drug: Ganetespib

First Posted Date: 2012-05-02

Last Posted Date: 2019-11-13

Lead Sponsor: University College, London

Target Recruit Count: 27

Registration Number: NCT01590160

Locations: 🇬🇧
UCL Cancer Trials Centre, London, United Kingdom

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Ganetespib

First Posted Date: 2012-03-23

Last Posted Date: 2015-05-20

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 12

Registration Number: NCT01562015

Locations: 🇨🇦
Synta Pharmaceuticals Investigative Site, Toronto, Ontario, Canada

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Ganetespib

First Posted Date: 2012-03-22

Last Posted Date: 2024-11-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01560416

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
New Hampshire Oncology and Hematology, P.A., Concord, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ganetespib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-12-06

Last Posted Date: 2015-10-12

Lead Sponsor: Emory University

Target Recruit Count: 8

Registration Number: NCT01485835

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 5 locations

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

Phase 1

Completed

Conditions: Acute Myeloid Leukaemia
High Risk Myelodysplastic Syndrome

Interventions: Drug: AC220
Drug: Plerixafor
Drug: Ganetespib

First Posted Date: 2010-11-08

Last Posted Date: 2014-06-11

Lead Sponsor: Cardiff University

Target Recruit Count: 113

Registration Number: NCT01236144

Locations: 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇬🇧
St Bartholomew's Hospital, London, United Kingdom

and more 10 locations

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Standard Therapy
Drug: AMG 386 with or without Trastuzumab
Drug: AMG 479 (Ganitumab) plus Metformin
Drug: MK-2206 with or without Trastuzumab
Drug: T-DM1 and Pertuzumab
Drug: Pertuzumab and Trastuzumab
Drug: Ganetespib
Drug: ABT-888
Drug: Neratinib
Drug: PLX3397
Drug: Pembrolizumab - 4 cycle
Drug: Talazoparib plus Irinotecan
Drug: Patritumab and Trastuzumab
Drug: Pembrolizumab - 8 cycle
Drug: SGN-LIV1A
Drug: Durvalumab plus Olaparib
Drug: SD-101 + Pembrolizumab
Drug: Tucatinib plus trastuzumab and pertuzumab
Drug: Cemiplimab
Drug: Cemiplimab plus REGN3767
Drug: Trilaciclib with or without trastuzumab + pertuzumab
Drug: SYD985 ([vic-]trastuzumab duocarmazine)
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug: Dan222 + Niraparib
Drug: Sarilumab + Cemiplimab + Paclitaxel
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug: Amcenestrant
Drug: Amcenestrant + Abemaciclib
Drug: Amcenestrant + Letrozole
Drug: ARX788
Drug: ARX788 + Cemiplimab
Drug: VV1 + Cemiplimab
Drug: Datopotamab deruxtecan
Drug: Datopotamab deruxtecan + Durvalumab
Drug: Zanidatamab
Drug: Lasofoxifene
Drug: Z-endoxifen
Drug: ARV-471
Drug: ARV-471 + Letrozole
Drug: ARV-471 + Abemaciclib
Drug: Endoxifen + Abemaciclib
Drug: Rilvegostomig + TDXd
Drug: AMG 386 and Trastuzumab

First Posted Date: 2010-01-05

Last Posted Date: 2024-10-22

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 5000

Registration Number: NCT01042379

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Kansas, Westwood, Kansas, United States

and more 33 locations

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: Ganetespib

First Posted Date: 2009-12-25

Last Posted Date: 2016-03-10

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 27

Registration Number: NCT01039519

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Oregon Health and Science University-Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy